EC approval of Rinvoq in Crohn's disease

The European Commission (EC) has approved Rinvoq (upadacitinib) as the first oral Janus Kinase (JAK) inhibitor for the treatment of adult patients with moderately to severely active Crohn's disease who have had an inadequate response, lost response or were intolerant to either conventional therapy or a biologic agent.

This is the seventh approved indication for US pharma major AbbVie’s (NYSE: ABBV) Rinvoq in the European Union (EU), such as across chronic immune-mediated diseases, including four in rheumatology, and the first and only oral JAK inhibitor approved to treat adult patients with moderately to severely active Crohn's disease.

Actual sales and forecasts